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Outpatients with CLBP who received at least one acupuncture session in a Korean 
Medicine clinic during the study period were included and followed up for 3 months. 
All patients received regular acupuncture treatments in accordance with the doc-
tors’ discretion. The clinical effects were measured by condition-specific outcomes 
and preference-based outcome. In terms of cost analysis, the cumulative resource 
use for direct medical costs at each research clinic during the study period and direct 
patient data using the self-reported health care utilization questionnaires were 
used. Results: A total of 105 patients were finally analyzed. Significant improve-
ments in condition-specific and preference-based measures were observed after 
acupuncture treatment. An average of approximately $134 per patient was reported 
for direct medical costs in each clinic for one month (8.5 sessions) and $213 for three 
months (13.5 sessions). Other medical expenses related to CLBP were reduced dur-
ing this period. ConClusions: Acupuncture to manage CLBP in general clinical 
practice in Korea, inexpensively improved pain, functional disability, and quality 
of life. The study results are meaningful and consistent with the results of previous 
randomized controlled trials performed in other European countries. A large-scale 
prospective cohort or registry based on practice may be helpful to strengthen the 
evidence of the cost-effectiveness of acupuncture.
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objeCtives: In the treatment of psoriatic arthritis (PsA), switching between alter-
native biologic treatments is common. A cost-effectiveness model was developed 
to assess the impact of placing apremilast, a new oral treatment, prior to biolog-
ics in PsA patients who had failed traditional DMARD therapy, from a U.S. payer 
perspective. Methods: A lifetime Markov state transition cohort model was 
developed which compared two treatment sequences in the base-case: apremi-
last followed by adalimumab followed by etanercept vs. adalimumab followed 
by etanercept. Patients who failed etanercept were assumed to receive best sup-
portive care (BSC) as the last line of treatment. Response to therapy was assessed 
using the Psoriatic Arthritis Response Criteria (PsARC) at the end of the clinical 
trial periods, ranging from 12 to 16 weeks depending on drug. Non-responders 
moved to the next line of therapy. A 16.5% annual drop-out rate was assumed for 
each drug. Treatment efficacy inputs were obtained from a meta-analysis and 
trial results. Drug costs were sourced from 2013 WAC prices, and a 3% annual dis-
count rate was applied to costs and QALYs. Apremilast was assumed to be priced 
at a discount to biologics. Utilities were estimated from HAQ and PASI response 
using a previously published regression equation. Results: The apremilast arm 
provided an additional 2.53 years with a PsARC response and an additional 0.78 
QALYs. Total time spent on the biologics was reduced by 0.34 years and time 
spent in BSC was reduced by 2.85 years. Under base-case assumptions, placing 
apremilast before biologics was found to be the dominant strategy (costs reduced 
by $28,794). Sensitivity analyses indicated that several parameters (e.g. cost of BSC 
and baseline utility) influence the ICER. Similar results were obtained with dif-
ferent biologic drugs in the sequence. ConClusions: Placing apremilast before 
biologics is a cost-saving strategy in the treatment of PsA.
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objeCtives: Osteoarthritis generally affects the joint functions of elderly patients 
causing significant pain and burden. There is no cure for osteoarthritis and treat-
ments tend to aim to alleviate pain and slow the progression of the disease. This 
study estimates the cost-effectiveness of celecoxib for treatment of osteoarthritis in 
China. Methods: The National Institute for Health and Clinical Excellence (NICE) 
developed a health economic model that was adapted to update the relative risks 
of adverse events using data from the CONDOR trial. This study localized the model 
to treatment patterns and costs in China. Comparators included celecoxib and 
diclofenac + PPI. The relative risks for adverse events were taken from the CONDOR 
trial. The base case patient was 55 years old. Treatment cycles were set to 3 months 
and the model ran for 180 cycles. Effectiveness was measured in quality-adjusted 
life years (QALYs). Costs and QALYs were discounted annually at 4.75%. Costs were 
reported in 2013 USD (1 USD = 6.07 RMB). Results: For celecoxib vs. diclofenac + 
PPI, using adverse event relative risks from the CONDOR trial, celecoxib has a cost of 
$3,707 and 8.805 QALYs while diclofenac + PPI has a cost of $3,757 and 8.813 QALYs. 
The incremental costs and QALYs of celecoxib vs. diclofenac + PPI are -$49.45 and 
-0.009 QALYs respectively. The incremental cost-effectiveness ratio for diclofenac 
+ PPI vs. celecoxib is $5,793. Drug costs account for 26% and 28% of the costs in 
the celecoxib and diclofenac + PPI arms, respectively. ConClusions: Celecoxib 
is a less costly alternative than diclofenac + PPI. The difference in QALYs between 
celecoxib and diclofenac + PPI is extremely small and through sensitivity analysis 
may not be significant.
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objeCtives: To estimate the 2-year cost per year in response of biologics for 
Rheumatoid Arthritis (RA) among US commercially insured adults. Methods: 
Adults (ages 18-63) newly initiating a biologic for RA (etanercept, abatacept, 
adalimumab, certolizumab, golimumab, and infliximab) were identified in the 
impairment (OWI) indexes. Additional questionnaires on patients’ characteristics 
and disease activity level, assessed on standardized scales: DAS28, PASI, CDAI, were 
added. Present economic activity (% of workers), presenteeism (time lost due to 
inefficient work), absenteeism (time of temporal absence caused by disease) and 
OWI ratios were calculated for each diagnostic group separately. Results: Of the 
three groups, patients with RA had the lowest rate of economic activity – 42%. 56% 
of CD patients and 57% of Ps patients worked for pay. Furthermore, productivity 
loss measured with OWI was highest in RA group: 43% of work time was lost. It was 
slightly better in CD and Ps groups, OWI amounted to 36% and 35% respectively. 
RA group had the highest absenteeism rate (18%) and also high presenteeism rate 
(27%), Ps group had the lowest absenteeism rate (9%) and the highest presenteeism 
rate (28%), CD group ranked between them with 16% absenteeism rate and 24% 
presenteeism rate. ConClusions: RA, CD and Ps all cause productivity loss, each 
in a different manner. M2W study is a unique national data source for indirect cost 
analysis for RA, CD and psoriasis.
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objeCtives: The aim of the study is to estimate the pension costs (social secu-
rity system in Italy is financed by public expenditure) induced by patients with 
musculoskeletal disorders (MD) and specifically for rheumatoid arthritis (RA), 
ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in Italy, between 2009 and 
2012. Methods: We analysed the database of National Institute of Social Security 
(INPS) for three types of social security benefits: disability benefits, disability pen-
sions (for people with reduced work ability) and incapacity pensions (for people 
without work ability). A probabilistic model with a Monte Carlo simulation was 
developed in order to estimate for MD, RA, AS and PsA, the total costs of the three 
types of benefits. For the estimation of the productivity loss for RA in the 2012, 
economic data (cost of work day) were collected from the databases of the National 
Institute of Statistics (ISTAT) and absenteism data from national literature review 
(Censis, Anmar, SIR, 2008; Leardini 2002; Salaffi 2005). Results: The model esti-
mated a total costs of € 311.534.554 ± € 31.849.117 in the 2009 and € 301.244.287 ± 
€ 33.871.230 in the 2012 for the disability benefits, € 11.163.392 ± € 3.047.946 in the 
2009 and € 10.560.086 ± € 3.079.987 in the 2012 for the incapacity pensions and 
€ 136.473.625 ± € 14.417.893 in the 2009 and € 123.608.660 ± € 13.734.418 in the 2012 
for the disability pensions. The productivity loss for RA in the 2012 amounted 
to € 1.145.377.593 ± € 100.396.928. ConClusions: The most important indirect 
costs in Italy in 2012 was represented by disability benefits (68% of the total cost), 
followed by disability pensions (30% of total indirect cost). A better prescription 
appropriateness and rapid access to innovative treatments (Italy, among the EU 
Countries, is the one with the greatest delay in access) would reduce the costs 
incurred by the social security system accompanied by an improvement on the 
effectiveness of interventions.
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objeCtives: We described the cost of the drug therapy for ankylosing spondylitis in 
the State of Minas Gerais, Brazil. Methods: We analysed data from the Outpatient 
Information System during March 2010 and February 2011 of the Brazilian Public 
Health System (SUS). We applied the probabilistic record linkage to match registers 
of the same patient and performed the analysis under the SUS’s perspective. We 
included patients over 18 years-old with diagnosis of ankylosing spondylitis who 
had begun the drug therapy after March 2010. We classified the patients in groups 
according to the initial therapy in anti-TNF agent users (infliximab, etanercept or 
adalimumab) or disease-modifying anti-rheumatic drugs-DMARD (the reference 
group). The cost was expressed in U.S. dollars. The analyses were performed with 
database manager system mysql and SPSS®19. Results: We indentified 236 anky-
losing spondylitis patients and 979 pharmacy claims. Mean age was 41.1 years 
(standard deviation 12.2) and most patients (70.0%) were men. Approximately 18% 
of patients withdrew the treatment. The total treatment expenditure in the study 
period was U$ 351,504.05; the cost with adalimumab represented 52.3% of this 
value. The estimated annual cost was U$ 117.53 for those who started sulfasala-
zine-DMARD treatment and ranged between U$ 3,251.08 and U$ 6,374.51 for anti-
TNF drugs. The median individual cost was U$ 2,553.90 for patients who initiated 
infliximab, U$ 2,516.44 for adalimumab, U$ 1,406.08 for etanercept and U$ 49.08 
for sulfasalazine-DMARD therapy. ConClusions: The cost of the anti-TNF agent 
treatment for ankylosing spondylitis is elevated. Therefore, the management of 
the public health system faces a challenge to offer an efficient and effectiveness 
patient care considering the limited public resources and the high demand for new 
health technologies.
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a ProSPEctivE obSErvational StudY for Evaluating thE coStS and 
clinical EffEctS of PatiEntS with chronic low back Pain
Kim S.Y.1, Lee H.1, Park S.K.2, Park H.J.1
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objeCtives: To investigate both clinical effects and costs of acupuncture under 
general medical practice for patients with chronic low back pain (CLBP) in 
Korea. Methods: A multicenter prospective observational study was performed. 
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objeCtives: To evaluate the cost-effectiveness of denosumab (Prolia®, 60 mg every 
6 month) compared to generic zoledronic acid (5 mg once yearly) in the treatment 
of postmenopausal osteoporosis in the U.S. societal perspective. Methods: 
Comprehensive literature and online search was employed to obtain data on the 
clinical effectiveness of drugs, health-related quality of life (HRQoL) of disease 
states and costs. Databases searched were PubMed and Google Scholar engine. A 
Markov cohort model was constructed within the framework of incremental cost 
effectiveness ratios (ICERs) and net monetary benefit analyses. Given that generic 
zoledronic acid dominates denosumab in the base-case scenario, only one-way 
sensitivity analyses were performed to evaluate the sensitivity of results to model 
parameters. Finally, threshold analyses were used to determine the price at which 
denosumab would be as cost-effective as generic zoledronic acid. Results: In the 
base-case scenario, generic zoledronic acid increased 0.003 QALYs and decreased 
$227 costs incrementally compared to denosumab. Assuming a willingness-to-pay 
threshold of $150,000 per QALY, the NMB value of generic zoledronic acid compared 
to denosumab was $679. In the one-way sensitivity analyses, generic zoledronic 
acid dominated denosumab in all scenarios when model parameters were var-
ied within a range of 10% -15%. The threshold analyses indicated that even at a 
zero price, denosumab would not be cost effective relative to generic zoledronic 
acid. ConClusions: Based on a U.S. societal perspective, generic zoledronic acid 
is more cost-effective than denosumab in the treatment of high-risk patients with 
postmenopausal osteoporosis.
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Osteoarthritis (OA) is the most common joint disease in the Chilean population, 
and its treatment is guaranteed under a governmental program called “Explicit 
Health Guarantees” (GES). The chronic use of the drugs covered, non-steroidal 
anti-inflammatory (NSAIDs) and selective COX-2 inhibitors, is associated with 
gastrointestinal and cardiovascular complications. objeCtives: To estimate the 
incremental cost-effectiveness ratio (ICER) of treating patients 65 years old (y/o) 
and older with Celecoxib compared to NSAIDs. Methods: A cost-utility analysis 
was performed using a Markov model. Effectiveness data and likelihood of adverse 
events were extracted from CONDOR, MEDAL, CLASS and TARGET studies. Resource 
use was obtained from the recommendations of clinical guidelines. Unit costs were 
extracted from Chilean secondary databases or costs studies (September 2012). 
Target population: Patients 65+ y/o with mild to moderate OA. Perspective: Chilean 
public health system. Interventions: Acetaminophen, Diclofenac, Celecoxib, and 
association with proton pump inhibitor (PPI: Omeprazole). Time horizon: 6 months 
for base case. Outcome: incremental cost per quality-adjusted life year (QALY). Costs 
were measured in Chilean pesos, and converted to USD. Sensitivity analyses were 
performed, including treatment period (3-24 month), age (55-65 y/o), eliminating 
cardiovascular benefits, among others. Results: The gained QALYs for Diclofenac, 
Acetaminophen and Celecoxib were 0.31, 0.33 and 0.37 respectively (0.35, 0.34 and 
0.40 QALYs for Celecoxib+PPI). Considering the cost of care and complications, com-
pared to Acetaminophen, Celecoxib reported an ICER of USD 3497/QALY (USD 1780/
QALY for Celecoxib+PPI). Compared to Diclofenac+PPI, the ICERs for Celecoxib and 
Celecoxib+PPI were USD 8408/QALY and USD 2778/QALY. The ICERs decrease slightly 
if the time horizon increases to 1 or 3 years. All these ICERs were under the Chilean 
GDP per capita. ConClusions: Using Celecoxib for OA is highly cost-effective com-
pared to other NSAIDs in the Chilean context, according to WHO recommendation, 
due to the lower incidence of complications.
PMS38
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objeCtives: In cost-effectiveness analysis, it is often necessary to characterize 
the incidence of events in patients with and without risk factors. Yet, the needed 
background incidence for patients without risk factors (incidence_no_risk) may be 
unavailable in the published literature. Previously, researchers have used the gen-
eral population incidence (incidence_pop), derived from epidemiological studies. 
However, when incidence_pop is used the model will overestimate the true inci-
dence because incidence_pop is a weighted average of the incidences in patients 
with and without risk factors. The purpose of this study was to develop a general 
method for deriving a true baseline risk (incidence_no_risk) using a downward 
adjustment of incidence_pop. This is illustrated with the condition of osteoporo-
sis. Methods: In osteoporosis, the fracture incidence for high-risk persons (inci-
dence_risk) can be calculated by the patient’s baseline risk times the relative risk 
increase (RR_risk) due to risk factors (incidence_risk = incidence_no_risk*RR_risk). 
Published studies report RR_risk, incidence_pop, and the prevalence of the risk 
factor (p). The fracture incidence in the study population can be represented as 
follows: incidence_pop = incidence_risk*p + incidence_no_risk*(1-p). Therefore: 
incidence_pop = incidence_no_risk*RR_risk*p + incidence_no_risk*(1-p) incidence_
pop = incidence_no_risk*((RR_risk*p)+(1-p)) incidence_pop/((RR_risk*p)+(1-p)) = 
incidence_no_risk Results: The resulting equation is: incidence_no_risk = inci-
dence_pop/((RR_risk*p)+(1-p)). We tested incidence_pop as the baseline fracture 
incidence in an osteoporosis model, which had consistently overestimated the true 
MarketScan® Commercial Database from January 2009-July 2013. The patient’s 
first biologic claim (index claim) defined their treatment cohort. Patients were 
required to have continuous enrollment 6-months prior and 24-months follow-
ing their index claim and have a pre-index RA diagnosis. Patients with pre-index 
biologic use (including ustekinumab) or a diagnosis for other conditions that the 
study biologics are approved for were excluded. Effectiveness was estimated using 
a validated, published claims-based algorithm. Medications were considered effec-
tive until any of the following criteria were met; biologic dose escalation, switching 
biologics, adding a new non-biologic RA medication, receiving > 1 intra-articular 
injection, adding a glucocorticoid, increasing glucocorticoid dose, or low treatment 
compliance (< 80%). Each failure event had a 90-day non-response period and 
patients could experience multiple failure events over the follow-up. Costs were 
the sum of RA-related medical, pharmacy, and drug administration costs post-index 
and were attributed based on the index biologic. Cost per patient-year in response 
was defined as RA-related costs divided by the time in response. Results: 8,193 
patients (mean age = 49, 78% female) met the selection criteria. Cost per year in 
response was lower for etanercept ($26,610) compared with abatacept ($40,457, 
p< 0.001), adalimumab ($28,031, p= 0.003), golimumab ($28,722, p= 0.030), and inf-
liximab ($40,507, p< 0.001). Certolizumab also had numerically higher cost per 
patient-year in response ($28,486) compared to etanercept; however, this was not 
statistically significant (p= 0.141), possibly due to a smaller sample size for certoli-
zumab (n= 184). ConClusions: Using this algorithm, etanercept was estimated as 
the most cost-effective RA biologic with the lowest cost per patient-year in response 
among FDA-approved biologics for RA.
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objeCtives: Rheumatoid Arthritis (RA) affects approximately 0.4% of the Latin 
American population over 16 years of age. [1] Decreased pain and disability pre-
vention may be possible with a early diagnosis and appropriate treatment. [2] The 
objective is to assess the cost-effectiveness (CE) of Etanercept in the treatment for 
moderate to severe RA, with previous antirheumatic drugs failure, in comparison 
with the rest of anti-TNF and IL-6 blockers available in Dominican Republic, from the 
health care payer’s perspective. Methods: A decision tree model was implemented 
to compare the costs and effectiveness of Etanercept (comparator, 25mg/ 2 times 
per week), Adalimumab (40mg/every two weeks), Infliximab (3 mg/kg at 0, 2 and 
6 weeks, then every 8 weeks), Rituximab (1000mg day 0 and 15, with reevaluation 
every 24 weeks) and Tocilizumab (8mg/kg every 4 weeks), all in combination with 
Methotrexate. The effectiveness measures were: American College of Rheumatology 
(ACR) Response Criteria ACR20 and ACR70. Quality utilities were obtained from 
Health Assessment Questionnaire (HAQ). Local costs (2013 US$) were obtained from 
Local Public Health databases. The outcomes were: total costs of RA (adverse events, 
exams and treatments) and QALYs gained. Probabilistic sensitivity analysis was 
performed. The time horizon was 2 years and the discount rate was 5% for costs 
and health outcomes. Results: The total cost of Etanercept was $US30,355.46, 
being $US1,968.70, $US175.92, $US3,930.32, and $US11,260.72 less expensive than 
Adalimumab, Infliximab, Tocilizumab and Rituximab respectively. Etanercept also 
gained the highest number of QALYs (1.5423) in comparison with adalimumab 
(1.5048), infliximab, (1.4299), tocilizumab (1.4955) and rituximab (1.4674). Cost-
effectiveness analyses showed Etanercept as the dominant strategy. Acceptability 
curves showed that at the willingness-to-pay of US$17200/QALY, the probability that 
etanercept is cost-effective met 100%. [3] ConClusions: Etanercept appeared as 
the most cost-effective alternative for RA against other anti-TNF and IL-6 blockers 
in Dominican Republic.
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rituxiMab aS firSt choicE for PatiEntS with rEfractorY rhEuMatoid 
arthritiS: a SYStEMatic rEviEw and coSt-EffEctivEnESS analYSiS
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objeCtives: Using rituximab for patients with rheumatoid arthritis who are 
refractory to conventional and/or biologic “disease modifying anti-rheumatic 
drugs” (DMARDs) is common choice of therapy in Iran. We evaluated the effec-
tiveness and cost-effectiveness of using rituximab for these patients in compari-
son to continuing conventional DMARDs, from a perspective of health service 
governors. Methods: A systematic review was implemented through search-
ing MEDLINE, Scopus and Cochrane Library. Inclusion criteria were being an RCT 
on rituximab, for refractory rheumatoid arthritis patients, and with a control 
group of DMARDs. Included articles were qualified by JADAD questionnaire. Risk 
Difference and CI95 were calculated and heterogeneity was tested by the Cochran 
Q test. To measure the direct and indirect medical costs, a set of interviews with 
patients were applied. Thirty two patients were selected from three referral clin-
ics in Tehran with definite diagnosis of refractory rheumatoid arthritis in the 
year before, and treatment regimen of either rituximab or DMARDs within last 
year. Incremental cost-effectiveness ratio was calculated using mean of costs 
for 6 months period and risk difference, with a scenario and sensitivity analy-
sis. Results: From 1875 related articles, 4 studies were eligible to be considered 
in this systematic review. Results of meta-analysis showed homogeneity of all 4 
studies and a total risk difference of 0.3 for ACR20 criteria, 0.2 for ACR70WR, and 
0.37 for EULAR criteria of response. Also mean of total medical costs of patients 
for one year were $7957 in rituximab group and $1861 for DMARDs group. Hence, 
the cost-effectiveness ratio will be $10159 per ACR20, $15238 per ACR70WR, and 
$8237 per EULAR in base case analysis, while in generic rituximab scenario shows 
a 30% reduction of results. ConClusions: Rituximab for patients with refractory 
rheumatoid arthritis does not seem to be cost-effective in Iran, although generic 
use of this drug can be encouraged.
